$$$ Nanobac! $$$ Produktionsstart der CNP-Diagnosetests - 500 Beiträge pro Seite

[paloma]

Endlich die Meldung! Nanobac startet die Produktion der CNP
-Diagnosetests.

Ein Vorschlage für Eure Watchlist.

Die News:

Nanobac Pharmaceuticals Inc. To Begin Domestic Manufacturing of Diagnostic Tests

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (\"Nanobac\" or \"the Company\") announces that its proprietary CE marked Nano-Capture ELISA assay and Nano-Sero IgG ELISA assay currently manufactured by the Company’s subsidiary in Kuopio, Finland, will be made in the United States for use in clinical trials, FDA approval and expanded distribution.

The Company’s diagnostics detect Calcifying Nano Particles (CNPs) which are linked to several diseases associated with pathologic calcification. The Company believes that its diagnostics will serve as biomarkers allowing for earlier identification, diagnosis, and treatment of such diseases.

“The technology transfer of our proprietary diagnostic to a FDA approved U.S. manufacturing facility is a hallmark event for our company,” commented Dr. Benedict Maniscalco, Nanobac’s Co-Chair and Chief Medical Officer. “Bringing our manufacturing to the United States will potentially allow us to make our diagnostic a standard of care in U.S. Healthcare and represents a key step to transition from a research oriented company to one that rapidly develops products for sales and marketing worldwide.”

For more information on the Company’s direction please refer to the Investor Section at www.nanobac.com. Further, for frequent updates on Nanobac’s progress please register as a friend of Nanobac at www.nanobac.com.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are \"Forward-Looking Statements\" within the meaning of the Private Securities Litigation Reform Act of 1995 (the \"Act\"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as \"believes,\" \"anticipates,\" \"intends,\" \"plans,\" \"expects,\" and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Nanobac Pharmaceuticals Inc., Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348


Source: Business Wire (August 16, 2007 - 7:03 AM EST)

News by QuoteMedia
www.quotemedia.com

[paloma]

Hier der RT-Chart:

[gony2]

naja waere ja schoen wnen die umsatz machen wuerden aber bisher ziemlichfehlanzeige.
ob die dinger nochmal steigen weis auch keiner so genau.
die umsaetze in den usa sind ja schwach.
und die hoechststaende weit weg.
bis jetzt hat die pr abteilung auch gearbeitet wie in einem comic film....naja mit viel hoffnung gehen wir wieder auf die 20 cent

[paloma]

Der News-Flow bei Nanobac und seinem CNP-Diagnosetest nimmt interessante Konturen an.

Die News von Gestern:

Nanobac Announces Results for Nanoparticle and Kidney Stone Formation Study

Results May Change Approach to Medical Management of Kidney Stones

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP)("Nanobac" or "the Company”) announces that scientists from the University of California San Francisco, collaborating with Nanobac scientists at NASA’s Johnson Space Center, have concluded research demonstrating that calcium deposits in the human kidney called Randall’s Plaque may in fact be Calcifying Nano Particles (CNPs, also referred to as nanobacteria) which lead to the formation of Kidney Stones.

The study, led by Marshall Stoller M.D. of UCSF and Neva Ciftcioglu, Nanobac’s Director of Science at NASA Johnson Space Center, found that CNPs were identified and cultured from Randall’s plaques and detected by Nanobac’s proprietary diagnostics. This could represent potential new early diagnosis and treatment opportunities for patients who suffer from Kidney Stones.

Neva Ciftcioglu stated: “A strong link was found between the presence of Randall’s plaques and the detection of CNPs. These results suggest new insights into the etiology of Randall’s plaque formation, and will help us understand the pathogenesis of stone formation. Further studies on this topic may lead to new approaches on early diagnosis and novel medical therapies of kidney stone formation.”

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348


Source: Business Wire (August 21, 2007 - 9:06 AM EST)

News by QuoteMedia
www.quotemedia.com

[paloma]

... um die Sache zu komplettieren. Nächste Woche ist ein Conference-Call für Investoren, Wissenschaftler und Presse anberaumt.


Die Mitteilung des Unternehmens (21.08.07):

Nanobac Pharmaceuticals Announces Investor, Scientific, and Media Conference Call

Corporate Scientists and Collaborators to Present Scientific Findings

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce it will host a conference call for shareholders, scientists and the media one week from today on Tuesday, August 28, 2007.

The company looks forward to discussing its progress and developments with shareholders, scientists, the media and the investment community. We look forward to updating interested parties on recent developments with regards to both our scientific and business initiatives.

Interested parties may hear and participate in the call by telephone.

To hear the conference call as it takes place:

United States - 1.800.434.1335
International/Direct Dial - 1.404.920.6442
Verbal Pass code: 554659#

To hear a recording of the call (available for 30 days following the
conference call):

United States - 1.800.428.6220
International/Direct Dial - 1.404.920.6443
Pin Code: 554659#

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information on the Company's direction please refer to the Investor Section at www.nanobac.com. Further, for frequent updates on Nanobac's progress please register as a friend of Nanobac at www.nanobac.com.

Forward-looking statements in this report are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. We wish to advise readers that actual results may differ substantially from such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the statements, including, but not limited to, the following: our ability to meet our cash and working capital needs, our ability to successfully market our product, and other risks detailed in our periodic report filings with the Securities and Exchange Commission.

For Nanobac Pharmaceuticals Inc., Tampa
Investor Contact:
Redwood Consultants, LLC
Jens Dalsgaard, 415-884-0348


Source: Business Wire (August 21, 2007 - 9:05 AM EST)

News by QuoteMedia
www.quotemedia.com

[paloma]

Die wollen uns nächste Woche offensichtlich was wichtiges mitteilen. Bin ja mal gespannt.

Nanobac Pharmaceuticals Announces Investor Presentation Available on Web Site

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP), "Nanobac” or "the Company” encourages shareholders and investors to view the new corporate presentation at www.nanobac.com.

Further, the company has announced a media, investor, and scientific conference call for Tuesday, August 28, 2007 at 4:15 PM Eastern Daylight Time. This call will be co-hosted by Alex H. Edwards III, Director, and Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer. Due to the overwhelming interest in the call, interested parties are encouraged to e-mail questions to [e-mail]. The company will do its best to answer all questions received before Monday 12 PM EDT.

Interested parties may hear and participate in the call by telephone.

To hear the conference call as it takes place:


United States - 1.800.434.1335

International/Direct Dial - 1.404.920.6442

Verbal Pass code: 554659#


To hear a recording of the call (available for 30 days following the conference call):



United States - 1.800.428.6220

International/Direct Dial - 1.404.920.6443

Pin Code: 554659#

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information on the Company's direction, please refer to the Investor Section at www.nanobac.com. Further, for frequent updates on Nanobac's progress, please register as a friend of Nanobac at www.nanobac.com.

Forward-looking statements in this report are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. We wish to advise readers that actual results may differ substantially from such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the statements, including, but not limited to, the following: our ability to meet our cash and working capital needs, our ability to successfully market our product, and other risks detailed in our periodic report filings with the Securities and Exchange Commission.

For Nanobac Pharmaceuticals Inc.:
Redwood Consultants, LLC
Jens Dalsgaard, 415-884-0348

Source: Business Wire (August 23, 2007 - 7:35 AM EST)

News by QuoteMedia
www.quotemedia.com

[Rainbowfu]

Interesse scheint zu steigen, mein Kaufauftrag in D wurde nicht erfüllt - will niemand verkaufen?

[kardoss12]

Antwort auf Beitrag Nr.: 31.271.008 von Rainbowfu am 23.08.07 16:55:23

es wäre das dummste was jetzt passieren könnte, wenn jemand nach den news verkaufen würde.

die aktie ist seit monaten sehr stark unterbewertet.
( wert aktuell : 0,20 - 0,45 USD )

vielleicht geht es noch in den USA etwas zu kaufen.
beeile dich.

[Rainbowfu]

Habe welche bekommen, aber noch ist es nicht soweit...ich denke, dass viele ihre Stücke nicht aus den Hand geben, ein großer Handel ist auch in den USA nicht zu verzeichnen. Der Kurs warte auch ab......

[paloma]

Antwort auf Beitrag Nr.: 31.274.356 von Rainbowfu am 23.08.07 21:23:49

Dies kann - erfahrungsgemäß, bei NNBP sehr schnell gehen. Aber es sind die erste Startformationen erkennbar.

Bin mal gespannt.

[DerToby]

Antwort auf Beitrag Nr.: 31.254.731 von paloma am 22.08.07 14:26:39

... Gibt es bald einen neuen Film über das Wesen der Nanos?

[paloma]

Antwort auf Beitrag Nr.: 31.279.051 von DerToby am 24.08.07 11:26:24

Nun, ob`s wieder ein Filmchen wird, weiß ich auch nicht.

Daß die uns wichtiges berichten wollen, liegt für mich auf der Hand. Welche Gründe sollte es sonst für den im Vorfeld groß angekündigten Conference-Call geben.

Mittlerweile werden auch die CNP-Test produziert. Hierzu gibts bestimmt auch interessante Informationen.
Sicherlich auch Informationen der kollaborativen Ergebnisse mit NASA, Mayo Clinic, Cleveland Clinic und anderen pharmazeutischen Partnern.

Bin sehr zuversichtlich.

[gony2]

Antwort auf Beitrag Nr.: 31.281.217 von paloma am 24.08.07 14:06:41

dein wort in gottes ohr.
als wir damals am durchbruch nach oben standen kamen sie mit einem miesen filmchen an. die pr abteilung kuemmert sich leider auch nicht viel um anfragen.
trotzdem habe ich hoffnung..............

[paloma]

Bin gespannt, wohin der Kurs wohl heute treibt. Rechne im Hinblick auf den morgigen Conference-Call damit, daß sich das Interesse Börsenende hin spürbar steigert.

[gony2]

Antwort auf Beitrag Nr.: 31.304.298 von paloma am 27.08.07 16:07:16

war wohl wieder nix

[Kardoss]

Antwort auf Beitrag Nr.: 31.323.972 von gony2 am 29.08.07 08:39:14

ich glaube an die wissenschaftler aus finnland und plane noch im sept. zukäufe zu machen.

[bua321]

so der Q-Report ist seit Gestern da !

[gony2]

Antwort auf Beitrag Nr.: 31.367.516 von bua321 am 02.09.07 14:12:57

und? kopie? inhalt?
milliarden umsatz angestrebt?

[bua321]

Antwort auf Beitrag Nr.: 31.374.326 von gony2 am 03.09.07 15:23:06

unter:

finance.yahoo nnbp selber nachzulesen !



oder hier für dich ! (geht leider nicht besser ! )



PERIOD ENDING 30-Jun-07 31-Mar-07 31-Dec-06 30-Sep-06
Total Revenue 2 5 2 24
Cost of Revenue 2 4 1 11

Gross Profit 1 1 2 13

Operating Expenses
Research Development 285 379 852 357
Selling General and Administrative 279 2,063 864 274
Non Recurring - - - -
Others 115 117 117 118

Total Operating Expenses - - - -


Operating Income or Loss (679) (2,558) (1,832) (736)

Income from Continuing Operations
Total Other Income/Expenses Net 7 (1,253) 30 2
Earnings Before Interest And Taxes (673) (3,810) (1,801) (734)
Interest Expense 44 46 62 53
Income Before Tax (717) (3,857) (1,863) (787)
Income Tax Expense - - - -
Minority Interest - - - -

Net Income From Continuing Ops (717) (3,857) (1,863) (787)

Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -


Net Income (717) (3,857) (1,863) (787)
Preferred Stock And Other Adjustments - - - -

Net Income Applicable To Common Shares ($717) ($3,857) ($1,863) ($787)


also wie ich sehen kann sind die Schulden sind wesentlich kleiner geworden !

[US336]

September 12, 2007 09:15 AM

Nanobac Pharmaceuticals Inc. Signs Agreement with American Health Associates Clinical Laboratories to Provide Calcifying Nanoparticle Tests in the United States
“Test Available 4th Quarter 2007”

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S.

The tests can detect CNP antigens and antibodies. Analysis will be performed at AHA’s main laboratory in Miramar. Nanobac’s laboratory in Finland will continue to service the world market after having performed thousands of such tests worldwide since the year 2000.

“This is the continuation of our new business strategy that was announced on our investor conference call three weeks ago,” commented Alex Edwards Director Nanobac Pharmaceuticals. “Making our diagnostic test for CNPs available under IUO conditions will help meet the growing demand from patients and physicians throughout the country. This is the first step toward acceptance of our NB2 test as a valuable health evaluation tool and potentially a standard of care in this country.”

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.


Contacts
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

[Rainbowfu]

Manchmal braucht man eben auch ein bisschen Geduld und ich bin der festen Meinung, dass diese Firma ihren Weg macht und dann zieht der Kurs auch wieder an.

[kardoss12]

Antwort auf Beitrag Nr.: 31.547.361 von US336 am 12.09.07 15:33:32

das, was der anleger gerne lesen will ist noch immer nicht dabei..

irgendwann müssen sie ja ihr wissen auch patentieren und lizenzen verkaufen...

es geht hier aber sehr vorsichtig mit der neuen businessstrategie vor
... unsicherheitsfaktor .... ?

[FlopBOB]

Antwort auf Beitrag Nr.: 31.547.361 von US336 am 12.09.07 15:33:32

Guten Tag!!

Wo is denn bei dieser Meldung der Unterschied zur Meldung vom 4. Okt. 2006

Flop

[kardoss12]

Antwort auf Beitrag Nr.: 31.575.586 von FlopBOB am 14.09.07 17:25:30

fortsetzung der zusammenarbeit mit NASA
http://home.businesswire.com/portal/site/google/index.jsp?nd…

[Saftladen]

[sachsenklebe]

Antwort auf Beitrag Nr.: 31.736.376 von Saftladen am 25.09.07 14:11:26

Was ist passiert

[Kardoss]

Antwort auf Beitrag Nr.: 31.737.804 von sachsenklebe am 25.09.07 15:50:37

September 25, 2007 08:00 AM Eastern Daylight Time


Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.83

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) today announced the release of an analytical profile on the Company by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a 12-month target value for NNBP of $0.83 per share.

The free report is available at: www.wallstreetresources.net/pdf/fc/NNBP2.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks.

Dr. Benedict Maniscalco, Co-Chair and Chief Medical Officer of Nanobac Pharmaceuticals, Inc. (NNBP), commented, "We are very excited that Wall Street Resources has issued an overall evaluation of our company with a 12 month target value of $0.83 per share.” Dr. Maniscalco further stated, "This report supports the Company’s belief that it is at the forefront of identifying and treating an underlying cause of a significant group of disease states that will translate to gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmaceuticals.”

Mr. Silver stated, "Nanobac is the leader in the science of calcifying nanoparticles and at the forefront of a potential paradigm shift, from reactive to proactive, in the diagnosis and treatment of many diseases related to its presence. Given that the direct and indirect costs of calcific disease exceeds $875 billion per year, the market opportunities for Nanobac are virtually limitless."

[GRIZZL]

Antwort auf Beitrag Nr.: 31.738.132 von Kardoss am 25.09.07 16:10:05

Und ich dachte schon,das es die Nachricht ist auf die alle gewartet haben.Hatten wir schon letztes Jahr so eine Analyse.
Nichtsdestotrotz bewegt sich der Kurs nach oben und das ist gut so.

[Lapalie]

[Kardoss]

Antwort auf Beitrag Nr.: 31.738.132 von Kardoss am 25.09.07 16:10:05

nanobac ist eine sehr riskante aktie... wenn es klappt dan geht der kurs mittelfristig auf 0,80 $ / bei grossem volumen.

wenn wir für längere zeit ins all fliegen wollen und z.b. später keine nierensteine nach 6 monaten bekommen, dann sind wir quasi gezwungen an nanobac zu glauben, so wie es die nasa tut. es gibt nich viele alternativen in diesem sektor.

schönen abend noch

[Rainbowfu]

An der OTC ist das meiste riskant, aber Nanobac hatte nach dem "freien Fall" einen Boden gebildet. Darauf konnte man etwas vertrauen, was das Risiko gemindert hat. Die Frage ist, auf was basiert diese Explosion. Solche News habe ich noch nicht gefunden, weiss Jemand mehr?

[Rainbowfu]

Vielleicht traut Amerika auch nur dem "respektierten Mikrokappe-Analytiker Herr Paul Silver, Direktor der Forschung für Wall Street Resources, Inc, der einen 12-monatigen Zielwert für NNBP von 0.83 $ pro Anteil(Aktie) enthält. Ich kenne den Mann nicht, aber viele Anleger glauben ihm wohl und treiben den Kurs, bis auf ?

[trickygirl]

Ooooooooooooooooooooh .......... meine Depotleiche wird grad reanimiert ............. sie zuckt ja schon seit 2 Tagen

[Lapalie]

Antwort auf Beitrag Nr.: 31.752.118 von Rainbowfu am 26.09.07 17:37:53

http://www.pinksheets.com/pink/quote/quote.jsp?symbol=nnbp#g…

Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.83

TAMPA, Fla., Sep 25, 2007 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) today announced the release of an analytical profile on the Company by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a 12-month target value for NNBP of $0.83 per share.

The free report is available at: www.wallstreetresources.net/pdf/fc/NNBP2.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks.

Dr. Benedict Maniscalco, Co-Chair and Chief Medical Officer of Nanobac Pharmaceuticals, Inc. (NNBP), commented, "We are very excited that Wall Street Resources has issued an overall evaluation of our company with a 12 month target value of $0.83 per share." Dr. Maniscalco further stated, "This report supports the Company's belief that it is at the forefront of identifying and treating an underlying cause of a significant group of disease states that will translate to gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmaceuticals."

Mr. Silver stated, "Nanobac is the leader in the science of calcifying nanoparticles and at the forefront of a potential paradigm shift, from reactive to proactive, in the diagnosis and treatment of many diseases related to its presence. Given that the direct and indirect costs of calcific disease exceeds $875 billion per year, the market opportunities for Nanobac are virtually limitless."

About Nanobac Pharmaceuticals, Inc.:

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

[Lapalie]

Antwort auf Beitrag Nr.: 31.762.225 von Lapalie am 27.09.07 13:59:46

Sorry,
wurde schon gepostet.

[gony2]

Antwort auf Beitrag Nr.: 31.762.261 von Lapalie am 27.09.07 14:02:09

Sieht ja heute wieder gut aus.
Bis zum euro ist es noch ein weiter weg

[Rainbowfu]

Aber nicht in diesem Tempo

[gony2]

Antwort auf Beitrag Nr.: 31.766.171 von Rainbowfu am 27.09.07 17:52:57

bei einem euro wuerde ich verkaufen aber ich erinner mich an viropharma..........

[angoli77]

sieht sehr sehr gut aus .....

[bua321]

drüben schöne Pakete aus dem Ask !

[bua321]

RT 0,16 $ he he !!!

[DerToby]

Antwort auf Beitrag Nr.: 31.768.073 von bua321 am 27.09.07 19:56:48

... das war mal ...

[bua321]

Antwort auf Beitrag Nr.: 31.768.096 von DerToby am 27.09.07 19:58:45

na Hauptsache die Luzzi funzt wieder !

[DerToby]

Antwort auf Beitrag Nr.: 31.768.119 von bua321 am 27.09.07 20:00:11

... und warum tut sie das?

[GRIZZL]

Bei 0,20 U$ bin ich wieder bei +-0.Danach rollt der Rubel,hoffe ich.
Jetzt brauchen wir noch ne Bomben Nachricht und dann ..

[bua321]

Antwort auf Beitrag Nr.: 31.768.141 von DerToby am 27.09.07 20:01:31

schau dir einfach mal die PR`s an !

[DerToby]

Antwort auf Beitrag Nr.: 31.768.319 von bua321 am 27.09.07 20:12:29

... ich habe mal etwas daraus durch Google übersetzen lassen:
..."die Marktgelegenheiten für Nanobac sind praktisch grenzenlos"
... das hoffe ich auch für die Kursentwicklung...

[Rainbowfu]

Ich denke, wir werden tatsächlich bis an erwähnten 80 US Cent rankommen und dann werden wir bis zu einer News konsolidieren. Nanobac hatte in den letzten Monaten ja nur eine News rausgebracht und der Kurs hat kaum reagiert, wenn man mal davon absieht, dass er einen festen Boden gefunden hat und nicht weiter runter marschiert ist. An den Dollar geht es erst mit News und auf die werden wir wohl warten müssen. Wenn diese aber kommen, dann geht die Post mit Nanobac wieder ab. Erfreulich, dass plötzlich wieder soviele hier sind.

[gony2]

Antwort auf Beitrag Nr.: 31.768.799 von Rainbowfu am 27.09.07 20:48:34

mir machen vor allem die umsaetze drueben mut

[angoli77]

supergeil ......

hoher umsatz und gesunde und nicht völlig überzogene kurssteigerungen ... zudem hier in D, bisher !!!, kaum beachtet ...

morgen 20C $

[Rainbowfu]

Die Beachtung wird kommen und dann kommen die BB und dann kommt Leben in die Bude....aber jetzt erstmal geniessen...

[angoli77]

SK 0,165 mit schönem ansteigendem volumen fast auf TH ( 0,167 ) .. geil

[trickygirl]

ich freu mich, hatte die schon abgeschrieben

[Rainbowfu]

...ich mich auch, Nanobac ist derzeit meine erklärte Lieblingsaktie

[paloma]

Hier dürfte dem weiteren Anstieg die Tür geöffnet sein!?

Nanobac Pharmaceuticals Board of Directors Approves Interim Financing and Stock Buy Back

Company and Management to Buy Back up to 20% of Float

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce that its Board of Directors has approved an interim financing package that will allow the Company to meet its scientific and business initiatives through the end of the year. This financing is a debt instrument which is being secured by management and should have minimal to no dilution to shareholders.

The Company’s Board of Directors also approved a stock buy back program which will allow for the Company and Management to buy back up to 20% of the outstanding float. This action was taken as a step to show management belief that the Company is significantly undervalued and the Board of Director’s commitment to the Company’s future success. This buy back will take place over the course of the next year.

“The significant advancements in our research and development program as well as our sales and marketing initiatives, makes these strategic moves the next logical step in the company’s progression,” commented Alex H. Edwards III, Director Nanobac Pharmaceuticals. “We are now actively interviewing investment banking firms to start the process of a significant funding event in late 2007 early 2008,” Edwards concluded.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241


Source: Business Wire (September 27, 2007 - 8:17 AM EST)

News by QuoteMedia
www.quotemedia.com

[Rainbowfu]

Freitag und dazu kleine Gewinnmitnahmen auf Grund des doch fulminanten Anstiegs. Ich denke, gegen Schluss werden wir nur noch leicht im Minus sein (Buyback-Programm wird das seinige dazu beitragen). Ist ja auch okay, am Montag gehts dann weiter in die richtige Richtung.

[hausmannskost]

Huuuuh der Wind, da wird es aber sehr schnell sehr hurtig nach unten gehen

[Rainbowfu]

oder es gibt erneut einen Ausbruch nach oben

[sanremo]

Was ist hier los, wie geht es weiter?

Toll wie das Teil abgeht.

[paloma]

Antwort auf Beitrag Nr.: 31.800.645 von sanremo am 01.10.07 09:06:53

Bis jetzt recht ordentlich.

[gony2]

Antwort auf Beitrag Nr.: 31.806.541 von paloma am 01.10.07 16:59:50

laueft doch ganz gut nach dem freitagsdesaster

[Rainbowfu]

ganz gut ist wohl etwas übertrieben. Ich verstehe diese doch recht großen Rücksetzer nicht so ganz. eigentlich hätte es doch heute wieder etwas nach oben gehen können...

[Rainbowfu]

Na, wenigstens haben sie sich gehalten. Einmal Luft holen, bevor es weiter nach oben geht? Bei der überraschend positiven Markteinschätzung müsste es doch weiter nach oben gehen....

[paloma]

Na also, warum nicht gleich Gestern.

[trickygirl]

Antwort auf Beitrag Nr.: 31.818.353 von paloma am 02.10.07 15:44:02

[paloma]

Antwort auf Beitrag Nr.: 31.818.440 von trickygirl am 02.10.07 15:48:24

News!

Nanobac Pharmaceuticals Announces Availability of Diagnostic Testing Services

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce that its diagnostic test, NB2, being offered through an agreement with American Health Associates (AHA) will be available by late October. Parties interested in getting tested are encouraged to start the specimen collection process as AHA is ready to receive NB2 specimens.

“We are extremely excited to make our diagnostic test available to patients and physicians in the United States as we had discussed in our investor conference call,” stated Alex H. Edwards III, Director, Nanobac Pharmaceuticals. “This is the first step in creating awareness of the NB2 test's utility in the Diagnosis and Management of patients with a multitude of diseases, and is the start of acceptance as a standard of care in healthcare,” Edwards concluded.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. Information on how to obtain an NB2 test is available at www.nanobac.com .

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

Source: Business Wire (October 2, 2007 - 8:22 AM EST)

[paloma]

Na dauert noch etwas. Die MM-Heinis müssen sich erst noch an die News gewöhnen.

[gony2]

Antwort auf Beitrag Nr.: 31.818.573 von paloma am 02.10.07 15:55:08

http://www.nanobac.com/content/nb2-request.cfm

[paloma]

dies werden noch heisse Stunden in Palermo, sorry Miramar.

AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S. The tests can detect CNP antigens and antibodies. Analysis will be performed at AHA's main laboratory in Miramar. Nanobac's laboratory in Finland will continue to service the world market after having performed thousands of such tests worldwide since the year 2000.

[trickygirl]

Antwort auf Beitrag Nr.: 31.818.703 von paloma am 02.10.07 16:02:25

Klasse news

[paloma]

Antwort auf Beitrag Nr.: 31.818.742 von trickygirl am 02.10.07 16:04:25

Die halten das, was sie auf dem Conferenc Call versprochen haben - im Gegensatz zu ...

[trickygirl]

Antwort auf Beitrag Nr.: 31.818.798 von paloma am 02.10.07 16:07:23

Keine Ahnung was du meinst?

[paloma]

Antwort auf Beitrag Nr.: 31.818.825 von trickygirl am 02.10.07 16:08:30

Erklär ich später. Muß leider dringend weg.

[Rainbowfu]

Nanobac war nicht umsonst schon bedeutend höher. Nach der jüngsten Einschätzung und den bisherigen News war der Kursverlauf gestern schon enttäuschend. Nach den Höhenflügen der letzten Woche ist ein Rückgang ja immer mal möglich, aber gestern war ich schon negativ beeindruckt, vielleicht versöhnt Nanobac,immerhin meine stärkste Position,mich ja heute dafür mehr.

[3cardinal]

Antwort auf Beitrag Nr.: 31.818.859 von paloma am 02.10.07 16:10:03

ich glaub ich weiss was du meinst...

[trickygirl]

Antwort auf Beitrag Nr.: 31.819.728 von 3cardinal am 02.10.07 16:53:18

ich weiß es auch ................. war doch nur ein Scherz

[FlopBOB]

Guten Tag!!

Möchte nur noch mal darau hinweisen, die Nachrichten etwas mit Vorsicht zu geniessen.

wallstreetresources hat letztes Jahr schon einmal eine Empfehlung gebracht, mit Kursziel $0,91 bis September 2007, also bis letzten Monat .

Jetzt haben sie sich also um 1 Jahr verschätzt und das Kursziel um 10% gesenkt. Letztes Jahr gings nach den gleichen News (wallstreetres., AHA usw.) auch schnell wieder bergab, aber schöne Zockergewinne sind sicher drin, aber Augen offenhalten und News hinterfragen.

Flop

[bua321]

viele hier haben die Tragweite der NEWS noch gar nicht erkannt !

[Rainbowfu]

Dieses Mal ist die Empfehlung aber mit News verbunden (u. a. Buy Back...)

[FlopBOB]

Antwort auf Beitrag Nr.: 31.822.521 von Rainbowfu am 02.10.07 20:11:03

Das war sie letztes Jahr auch.
Das mit der Finanzierung ist ja auch dringend nötig gewesen. Dennoch sollte es stutzig machen, dass fast die gleichen News wie vor einem Jahr jetzt noch einmal veröffentlicht werden. Mit AHA wird schon seit letztem Jahr zusammengearbeitet

AMPA, Fla., Oct 04, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S.

und ein Blick auf die Zahlen gibt weiteren Aufschluss.

Letztes Jahr, als die Meldung kam, wurde die Website von AHA einen Monat vorher erst gehostet, imo seltsam für so ein berühmtes Labor usw. usf..

Ich bin weiterhin misstrauisch, aber wie man sieht, kann man hier gute Gewinne erzielen.

Flop

[Rainbowfu]

Ja, Gewinne lassen sich erzielen, wenn man risikofreudig ist, denn die Spanne zwischen bid und ask ist doch immer noch recht hoch

[US336]

October 03, 2007 09:15 AM

Nanobac Pharmaceuticals Acquires Option to License Calgenex Technology to Treat Atherosclerosis and Prostatitis


TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announced today that it signed an agreement with Calgenex granting Nanobac an option to assess Calgenex’ drug delivery technology for potential use with Nanobac’s drug combinations used in treating atherosclerosis, prostatitis, and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid.

“Today’s option agreement is a testament towards our goal of evaluating the best therapeutic delivery technologies used with our compounds to treat diseases associated with pathologic calcification,” commented Alex H. Edwards III Director, Nanobac Pharmaceuticals. “We will be evaluating the Calgenex technology in the context of our drug development efforts in order to improve on an important class of drugs, namely bisphosphonates.”

There are a number of bisphosphonate drugs on the market including Fosamax, Evista, Actonel, and most recently Boniva. The administration of these drugs has been historically problematic. Advances in delivery mechanisms, such as enteric coatings and extended release formulas have helped with patient compliance, however challenges still exist. Nanobac is investigating the use of Bisphosphonates in combination with other approved compounds for the treatment diseases associated with soft tissue calcification, including atherosclerosis and prostatitis.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.


Contacts
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

[paloma]

Yepp! Auffi!
Fundamente für weiteren Anstieg sind zur Genüge geschaffen. Orderbuch verpricht auch positive Wertentwicklung.

[Rainbowfu]

Wie verträgt sich das mit dem Kurs? Oder wird einfach wild hin und her ge- und verkauft?

[gony2]

Antwort auf Beitrag Nr.: 31.847.353 von Rainbowfu am 04.10.07 20:28:14

naja der umsatz faellt langsam aber sicher auf das niveau von vor der studie zurueck.
sehr schade.

[Rainbowfu]

Es ist ein bisschen traurig....das sie wieder so weit fällt, glaube ich nicht, aber de facto scheint das Interesse wieder nachzulassen. Ein kurzes Aufbäumen und mehr nicht?

[gony2]

Antwort auf Beitrag Nr.: 31.849.161 von Rainbowfu am 04.10.07 22:56:44

Wer ist denn eigentlich alles in Nanobac hier investiert. Einfach die Anzahl der Leute wuesste ich mal gerne und was glaubt ihr denn wie es weitergeht. Also die Srudien heben ja nicht gerade Nanobac an die Euro Marke. Also was kommt da noch wenn man ja sagt das an der Boerse die Zukunft gehandelt wird?

[Rainbowfu]

M. M. nach hat Nanobac Potenzial, steht aber erst am Anfang, mit viel Forschung aber wenig Produktivität. Wenn sich das ändert, fliegt der Deckel. Die PR Abteilung unternimmt m. E. recht wenig, um sich Positiver in Szene zu setzen. Die letzten News hätten den Kurs dennoch etwas mehr unterstützen dürfen. Noch glaube ich dran

[paloma]

Antwort auf Beitrag Nr.: 31.904.029 von Rainbowfu am 08.10.07 21:33:12

Ich bleib dabei.

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce that its diagnostic test, NB2, being offered through an agreement with American Health Associates (AHA) will be available by late October.

[Rainbowfu]

Ich glaub daran und bleib natürlich dabei

[Christoph14031985]

bin auch shcon ne weile dabei. bei 0.054 eingestiegen. bin ganz zufrieden mit der entwicklung. hab 50% plus. bleibe auch weiter drin. denn ncoh ist es auch so, das dieser wert ABSOLUT unbekannt ist. und viele investoren kann es nicht geben, sonst gäbe es meiner meinung nach mehr umsatz und dann wär es auch einfacher einzusteigen, oder zu verkaufen. bin wie gesagt überzeugt davon das hier nochmal was passiert.

[paloma]

Antwort auf Beitrag Nr.: 31.916.328 von Christoph14031985 am 09.10.07 19:41:42

Überzeugt bin auch ich. Mir persönlich sind Werte, die fundamental mit Substanz ausgestattet sind lieber als die von Börsenblättchen und Foren hin- und hergetriebene leere Hülsen. Momentan stehen wir wieder an den relativ hartnäckigen Widerstand bei 0.14 $. Bin gespannt, wie lange der noch als solcher zu titulieren ist.

[3cardinal]

Antwort auf Beitrag Nr.: 31.927.179 von paloma am 10.10.07 16:38:31

so, der Widerstand wäre dann wohl nach unten durchbrochen...
war wohl doch nicht so stark, der Widerstand...

[Rainbowfu]

Der Widerstand ist extrem, aber bei 0,11 wohl auch eine Unterstützung. Allerdings kann ich das Volumen nicht verstehen, nach den Käufen im September nun sehr viel Verkäufe. Ignoranz der News, zittrige Kleinanleger, geringer Bekanntheitsgrad, was ist es?

[Rainbowfu]

"Nanobac erwirbt Option zur Lizenzierung Calgenex Techn. zur Behanldung v. Atherosklerose, Prostatitus", kündigt Verfügbarkeit von diagn. Tests an, Verwaltungsrat billigt Rückkauf, angebl. Ziel 0,83US Cent und was passiert....kurzer Ausreisser nach oben und dann wieder Konsolidierung? Ich glaube, wir brauchen viel Zeit, denn am Ergebnis zweifel ich nicht.

[Rainbowfu]

Alleine hier? Ich glaube aber nach wie vor, in US hält die 0,11

[bua321]

Antwort auf Beitrag Nr.: 31.963.094 von Rainbowfu am 12.10.07 21:58:08

ne bist nicht allein !
gibt halt im Moment nicht viel zu sagen !
warten wir mal Ende Oktober ab !
dann sehen wir weiter !

[Rainbowfu]

Kurz unter die 0,11 US Cent gefallen und doch wieder gedreht. Ich glaube, wenn diese Marke hält, wird es wieder hochgehen

[gony2]

Antwort auf Beitrag Nr.: 32.004.545 von Rainbowfu am 15.10.07 18:18:20

desaster

[paloma]

Immer wieder schön zu beobachten, wie in regelmäßigen 60K-Paketen gesammelt wird. Vermute dahinter das Stock Buy-Back-Programm, welches Nanobac ja ankündigte. Sie wollen 20 % des Free-Float aufsammeln.

Man bedenke auch die Ankündigung der Verfügbarkeit der Tests:

"Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce that its diagnostic test, NB2, being offered through an agreement with American Health Associates (AHA) will be available by late October."

Wäre alles schlüssig.

[paloma]

Antwort auf Beitrag Nr.: 32.067.077 von paloma am 18.10.07 16:24:25

Ich lehne mich jetzt einfach mal aus dem Fenster:

Nächste Woche wird Fahrt in den Kurs kommen. Ich stütze mich auf die Ankündigung seitens Nanobac, in der die NB2 Diagnostic-Test verfügbar sein sollen (by late October). Wird sicherlich von einer Meldung begleitet.

Immer wieder schöne 60k und 100k-Käufe die letzten 2 Wochen. Ich vermute das Aktienrückkauf-Programm von Nanobac.

[paloma]

Antwort auf Beitrag Nr.: 32.088.679 von paloma am 19.10.07 19:35:43

Nanobac Pharmaceuticals Inc. Announces NB2 Test for Calcified Nano Particles Now Available

American Health Associates Clinical Laboratories is Accepting Patient Samples in the United States

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) are pleased to announce that AHA is accepting blood samples from across the U.S. for Nanobac’s NB2 test.

“There has been a continuous, significant and strong demand for our NB2 test since we made our announcement in September that AHA would provide testing services for the Company’s NB2 diagnostic test in the fourth quarter,” commented Dr. Benedict Maniscalco, Chief Medical Officer, Nanobac Pharmaceuticals. “We are pleased that AHA is now accepting specimens, which is in line with our business strategy announced on our August investor conference call.”

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

American Health Associates is headquartered in Miramar, Florida. For information on AHA, and how to access the NB2 testing, visit their website at http://www.americanhealthassociates.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348


Source: Business Wire (October 23, 2007 - 10:09 AM EDT)

[Rainbowfu]

Antwort auf Beitrag Nr.: 32.121.980 von paloma am 23.10.07 16:27:08

a) freut mich, dass außer mir noch Jemand da ist
b) die Nachricht freut mich noch mehr
c) ich glaube schon lange an Nanobac und ich werde weiter glauben
in diesem Fall heißt glauben aber nicht nicht wissen

[Rainbowfu]

Nanobac Pharmaceuticals, Inc. Announces NB2 Test für Calcified Nano Partikel jetzt verfügbar
Tuesday October 23, 9:15 am ET
dazu Rückkaufprogramm, erwähntes Ziel...
wir kommen, wir kommen langsam und wir müssen Hindernisse verschieben, aber wir kommen

[paloma]

Vertriebsvereinbarung! News von Heute

Nanobac Pharmaceuticals Inc. Announces Diagnostic Products Distribution Agreement with DPC-Lebanon for the Middle East
10/25/2007
TAMPA, Fla., Oct 25, 2007 (BUSINESS WIRE) --

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce the signing of an exclusive distribution agreement with DPC-Lebanon (DPCL) covering Lebanon, Syria, Jordan, Iraq, Kuwait, Saudi Arabia, United Arab Emirates, QATAR, Bahrain, Oman, and Egypt.

"Our worldwide demand for CNP diagnostic products is increasing as CNPs or nanobacteria are implicated in more and more chronic diseases," stated Dr. Benedict Maniscalco, Nanobac's Chief Medical Officer. "These kits are CE marked and ready for immediate shipment throughout the European Union and the Middle East."

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

For more information on DPCL, visit their website at http://www.dpcleb.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

SOURCE: Nanobac Pharmaceuticals Inc.

Nanobac Pharmaceuticals, Tampa Brady Millican, 813-264-2241 or Redwood Consultants Jens Dalsgaard, 415-884-0348
Copyright Business Wire 2007

[Rainbowfu]

...mit CE Zeichen und bereit für Lieferung in EU...deshalb auch die 5% in US. Nur, wie entscheidend verändert das die MK? Aber die pos. Meldungen mehren sich und ich bleib natürlich dabei

[paloma]

Weitere interessante News zu Nanobac.

Nanobac Pharmaceuticals Inc. to Present at the Fall Life Sciences Conference in New York
10/29/2007
Premier Event to Be Held November 1st

TAMPA, Fla., Oct 29, 2007 (BUSINESS WIRE) --

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") today announced that it has been invited to present at Friedland Investment Events' Life Sciences Conference in New York. The Conference will be held November 1st at the DoubleTree Hotel Times Square, 1568 Broadway (47th / 7th), New York.

The Life Sciences Conference will feature presentations by senior management of publicly traded companies in the biotech, healthcare, medical devices and pharmaceutical industries.

Senior management of Nanobac's presentation will include a review of current operations, and most importantly the company's plans for the future.

Commenting on the company's participation at the conference, Dr. Benedict Maniscalco, Nanobac's Chief Medical Officer stated, "Nanobac is enthusiastic that our participation and presentation at the Life Sciences Conference in New York will provide the opportunity to update select and invited representatives of buy-side and sell-side firms regarding the company, and most importantly, our plans for the future."

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

About Friedland Investment Events

Friedland Investment Events LLC, the sponsor of the Global Equities Conference, is the world's largest sponsor of financial and investment events, sponsoring hundreds of conferences, luncheons, dinner, cocktail receptions and road shows annually throughout the United States.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company's operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

SOURCE: Nanobac Pharmaceuticals Inc.

Nanobac Pharmaceuticals, Tampa Brady Millican, 813-264-2241 or Redwood Consultants Jens Dalsgaard, 415-884-0348 or Friedland Investment Events LLC Patti Cannon, 303-800-0716 www.friedlandevents.com
Copyright Business Wire 2007

[bua321]

bin auch schon lange dabei !
aber wie so oft viel zu hoch eingekauft !
na dass kann ja noch was werden !

[paloma]

zunehmendes Interesse vor der Präsentation bei der Fall Life Sciences Conference in New York.

Termin 1.11.07

[Rainbowfu]

Antwort auf Beitrag Nr.: 32.088.679 von paloma am 19.10.07 19:35:43

Definitiv zu weit aus dem Fenster gelehnt Ich hoffe nur, dass der Kurs nach dem 1.11. auch die richtige Richtung einschlägt, erwarten könnte man dies eigentlich. Es fehlen im Prinzip nur die Anleger, die wieder oder immer noch an Nanobac glauben.

[Rainbowfu]

Jetzt lehne ich mich mal aus dem Fenster: Ich gehe von steigenden Kursen vor allem für den Rest der Woche aus und glaube, dass wir die 0,2$ erreichen.

[Rainbowfu]

Die Life Sciences Konferenz wird Präsentationen von Senior Management von börsennotierten Unternehmen in der Biotechnologie, Gesundheitswesen, medizinische Geräte und der pharmazeutischen Industrie.

Senior Management von Nanobac 'Präsentation wird auch eine Überprüfung der derzeitigen Operationen sind, und vor allem die Firma "Pläne für die Zukunft.

So unsauber die Übersetzung, so sauber wird der Kurs werden...und außer mir niemand mehr da?

[paloma]

Antwort auf Beitrag Nr.: 32.224.252 von Rainbowfu am 31.10.07 20:21:58

Doch. Kann aber nicht überall sein.

Geduld, Perlentaucher. Wir haben hier ein Unternehmen, das seine Hausaufgaben macht, ohne sich dabei großartig zu beweihräuchern.

Dies ist dann unser Job - ab 0.2 $

[bua321]

bin auch dabei !

[Rainbowfu]

Antwort auf Beitrag Nr.: 32.226.491 von bua321 am 01.11.07 01:30:09

Das Umfeld ist aber auch nur schlecht, müssen wir noch warten, bis Nanobac andere Höhen erreicht

[gony2]

Antwort auf Beitrag Nr.: 32.333.309 von Rainbowfu am 07.11.07 22:18:19

[Rainbowfu]

weiss irgendjemand, was hier los ist?

[DerToby]

... das war's dann wohl ... ... ... ... ... ... ... ... ... ... ... ...

[Saftladen]

Antwort auf Beitrag Nr.: 32.744.200 von DerToby am 12.12.07 19:51:08

[DerToby]

... wer da wohl in Frankfurt soviel bekommen/bezahlt hat?

[spiritrob]

Antwort auf Beitrag Nr.: 32.772.710 von DerToby am 15.12.07 08:27:31

muss ein gewaltiger optimist sein.
70% aufschlag, wow!

ich wollte eigentlich auch einsteigen,
aber mein limit bei 0,04 hatte da
natürlich keine chance

[bua321]

huch 20 % Plus gerade ! das wird hier doch nicht nochmal abgehen wollen ?
LG
und ein super neues jahr 2008 uns allen hier
bua

[springbok]

Ich bin vor über 12 Monaten eingestiegen und weiss gar nicht wie ich über die Nano gestolpert bin und habe mich zu hoch eingekauft mit einer sehr hohen Stückzahl.

Immer in der Hoffnung,entweder die haben einen Durchbruch oder ich einen Totalverlust.

Die Suche wird in medizinischen Kreisen sorgfälltig beobachtet,denn wenn Nano nachweisen kann,das man die Kalziumentwickelung in den Adern nachweissen und behandeln kann,dann ist der Durchbruch ein Grosser.

Aber machen dann die Pharmas mit, die mit vielen Medikamenten aus dem Rennen geworfen würden.
Habe mehrere Beiträge auf diesem Gebiet in den Thread gestellt.

Guten Rutsch in Neue Jahr.

Gruss Springbok

[springbok]

Antwort auf Beitrag Nr.: 32.895.422 von springbok am 29.12.07 18:07:54

Habe in der London Lancet Medical Magazin gelesen das Nanobac auf dem Wege eines Durchbruchs ist.
Nach dieser Nachricht werde ich meine Nano nicht verkaufen.

Sollte Nano ein Durchbruch gelingen dann geht die Aktie durch die Decke.

Manchmal muss halt eben warten.

Gruss Springbok

[bua321]

Antwort auf Beitrag Nr.: 33.106.000 von springbok am 19.01.08 19:33:00

kannste mal den Bericht reinstellen ? oder einen Link dazu !

wir scheinen hier die letzten Beobachter vonn nnbp zu sein !
grüssle
bua

[bua321]

hier die letzte PR von NANOBAC :

Press Release Pressemitteilung Source: Nanobac Pharmaceuticals Inc. Quelle: Nanobac Pharmaceuticals Inc.

Nanobac Announces Baylor College of Medicine Initial Results for Nanoparticle and Gall Stone Formation Study Nanobac kündigt Baylor College of Medicine erste Ergebnisse für Nanopartikel und Gallensteinextraktion Formation Studie
Tuesday January 15, 10:23 am ET Dienstag 15. Januar, 10.23 Uhr ET

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB: NNBP ) ( “ Nanobac ” or “ the Company ” ) announces that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones). TAMPA, Florida - (BUSINESS WIRE) - Nanobac Pharmaceuticals Inc. (OTCBB: NNBP) ( "Nanobac" oder "das Unternehmen") gibt bekannt, dass Wissenschaftler an der Baylor College of Medicine, arbeiten im Rahmen einer kooperativen Vereinbarung mit Nanobac haben Zitiert Beweise dafür vor, die Präsenz der verkalkend Nanopartikel (CNPs) und chirurgisch resezierten gallbladders mit Cholelithiasis (Gall Stones). This potentially represents a previously unrecognized factor in the development of cholecystitis and cholelithiasis disease. Dies stellt möglicherweise eine zuvor unbekannte Faktor in der Entwicklung der Cholelithiasis Cholezystitis und Krankheit.
The project seeks to determine if human cell derived nanoparticles are pathogenic and induce inflammatory (cholecystitis) and calcific pathologic (cholelithiasis) disease. Das Projekt soll, um festzustellen, ob menschliche Zellen abgeleitet sind Nanopartikel pathogenen und entzündlichen induzieren (Cholezystitis) und calcific pathologischen (Cholelithiasis) Krankheit. The project also seeks to confirm prior Nanobac studies, conducted in China, that Nanobac ’ s diagnostic test specifically identifies CNPs. Das Projekt zielt ferner darauf ab, um zu bestätigen, bevor Nanobac Studien, die in China, dass Nanobac 's Diagnosetest speziell identifiziert CNPs.

The study results suggest a strong association between CNPs and cholelithiasis and conclude that it is conceivable that a specific therapy for CNPs may prevent cholecystitis and reduce the need for surgical intervention. Die Ergebnisse der Studie legen nahe, eine starke Assoziation zwischen CNPs und Cholelithiasis und feststellen, dass es denkbar ist, dass eine spezifische Therapie für CNPs kann verhindern, Cholezystitis und reduzieren die Notwendigkeit einer chirurgischen Intervention. The results were given at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Die Ergebnisse wurden auf der 58. Jahrestagung der American Association for Study of Liver Diseases. The abstract was published in “ Hepatology 46(4) 699A 1036 Suppl S, 2007 ” issue. Die Zusammenfassung erschien in der "Hepatology 46 (4) Suppl. S 699A 1036, 2007".

Dr. Maniscalco, co-chair of Nanobac, stated, “ We believe that CNPs play a major role in pathologic calcification and a multitude of associated disease states such as calcification of arteries and organs. Dr. Maniscalco, Ko-Vorsitzender der Nanobac, sagte: "Wir glauben, dass CNPs spielen eine wichtige Rolle bei der pathologischen Verkalkungen und eine Vielzahl von damit verbundenen Krankheit Staaten wie Verkalkung von Arterien und Organen. This study, conducted by one of the lead medical and research facilities in the United States, lends credence to our beliefs. ” Diese Studie, die von einer der führen-und medizinischen Forschung in den Vereinigten Staaten, verleiht Glauben zu unseren Überzeugungen. "

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. Nanobac Pharmaceuticals Inc. mit Sitz in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com . Für weitere Informationen, besuchen Sie unsere Website unter: http://www.nanobac.com.

[springbok]

Antwort auf Beitrag Nr.: 33.109.173 von bua321 am 20.01.08 17:39:25

Werde mich einmal darum kümmern,aber dies liegt eine weile zurück.

Muss die Webseite ausfindig machen.

Gruss Springbok

[spiritrob]

Nanobac Announces European Heart Journal Publication of Association Between Calcifying Nanoparticles and Aortic Stenosis
Tuesday January 22, 10:59 am ET


TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company”) announces the multicenter publication of independent research which reports an association between calcifying nanoparticles (CNPs) and aortic stenosis. Aortic stenosis represents the most frequent cause of heart valve replacement (Bratos-P rez et al, European Heart Journal Advance Access, doi:10.1093/eurheartj/ehm592).


The authors contend: “For the first time, this study shows that CNP could be causally related to aortic stenosis in humans. We suggest that CNPs colonize the aortic valve, provoking an inflammatory response, resulting in valve calcification via two distinct mechanisms: directly given their capacity to precipitate calcium in the shape of apatite crystals, at physiological calcium and phosphate concentrations, and indirectly by activating the inflammatory pathways.”

“Although the finding of nanoparticles in such a significant number of patients with calcific aortic stenosis does not establish that such particles influence this condition, the question of such influence now `begs' to be answered,” said Richard A Berger MD.FACC., Asst Professor of Cardiology University of Miami Medical School.

Diagnosis for the presence of CNPs in these patients may be of help in learning more about this frequently fatal disease. Aortic valve stenosis affects 2-8% of adults over the age of 65, and is the number one indication for surgical valve replacement in the US and Europe. Nanobac has developed proprietary diagnostics to identify patients that could benefit from therapy for preventing the advance of this disease to stages needing surgery. Valve replacement surgery is currently the only curative treatment, but it is limited to patients of younger age, better health and has the limitation of the need for anticoagulant therapy not suitable for all patients. Nanobac also has therapies that treat CNPs, and could eliminate the need for surgery.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

[paloma]

Nanobac Pharmaceuticals Inc. Signs LOI for the Acquisition of DNAPrint Genomics
2/1/2008
TAMPA, Fla., Feb 01, 2008 (BUSINESS WIRE) --

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") is pleased to announce a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc. (OTCBBNAG) ("DNAPrint" or DNAP). With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development. Nanobac adds advanced drug and diagnostics development programs, key patents and patent applications, and a proprietary product modeling platform to its existing initiatives, and expands its focus into multiple disease sites for both Diagnostics and Therapeutics.

The combined company would have annualized revenue of approximately $5,000,000, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University.

DNAPrint Genomics has developed, patented and published various technologies for an improved, 21st century model of clinical product development - aimed at maximizing effectiveness, minimizing unintended effects, reducing costs and shifting the risk to reward ratio during clinical product development. These tools include extensively validated and published genome assays for individualized assessments of genetic ancestry on multiple levels (consumer products segment), tools for the inference of physical characteristics for the forensics market, tools for the inference of patient proclivities to respond to treatments (pharmacogenomics) and meta-analytical systems for computationally modeling the biology of clinical products for a more intelligent approach to drug and diagnostic development. DNAG's primary objective has been, and Nanobac's primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters. DNAG's flagship product, PT-401, is expected to result in more effective treatment of anemia, and its Protectin(TM) (CD-59) diagnostic test is expected to allow patients and their physicians to more effectively manage the risks and treatment decisions for diabetes. DNAG supports its clinical programs, in part, through the sale of consumer genetics tests genotyping services on a contractual basis.

"Dr Hector Gomez has been on the Company's advisory board giving Nanobac the benefit of evaluating DNAG's technologies and portfolio of products," said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals. "Combining our diagnostic portfolios, specifically DNAP's Protectin(TM) and Nanobac's NB2 has the potential to play a significant role in the early diagnosis of vascular disease and could potentially help in identifying early signs and progression of cardiovascular disease," Dr. Maniscalco concluded.

"The Protectin(TM) test will be used to identify diabetics at risk of developing vascular complications," said Dr. Gomez, Chairman of DNAP. "Protectin(TM) is anticipated to become a new tool in the complex understanding of Diabetes and could potentially replace HbA1c, the current test used to evaluate glucose control. Combined with Nanobac's diagnostic portfolio, Protectin(TM) is expected to dramatically increase the physician's ability to diagnose patients at significant cardiovascular risk," concluded Dr. Gomez.

According to Global Industry Analysts, the international global diabetes diagnostic supplies market is expected to grow to US$15.4 billion by 2010. This indicates significant potential for the Protectin(TM) test. Additionally, cardiovascular diagnostics will see a high rate of growth also, increasing from $11.9 billion in 2007 to $21.4 billion by the end of 2012. The cardiovascular diagnostics market represents one of the largest sectors within the diagnostics industry, chiefly due to the high prevalence rate of and high mortality rate from cardiovascular disease.

DNAG's flagship PT-401 therapeutic, in pre-clinical stages, is a genetically engineered erythropoietin dimmer (double form), which elicits a heartier, longer lasting increase in hematocrit for anemic patients. The singlet form of erythropoietin was introduced by Amgen Corporation in 1989, and enjoys a $2B in annual sales. A successfully approved PT-401 alternative is expected to allow physicians to treat patients with less drug and at less frequent intervals, at significant savings, while at the same time, increasing the consistency of therapeutic response.

Nanobac Pharmaceuticals is the leader in research and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac Pharmaceuticals markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

SOURCE: Nanobac Pharmaceuticals Inc.

Nanobac Pharmaceuticals, Tampa Brady Millican, 813-264-2241 or Redwood Consultants Jens Dalsgaard, 415-884-0348
Copyright Business Wire 2008

[paloma]

FFM +160,00 %
Volumen 2500 Shares

[spiritrob]

Antwort auf Beitrag Nr.: 33.243.193 von paloma am 01.02.08 19:16:56

ja, echt witzig

[springbok]

Antwort auf Beitrag Nr.: 33.109.173 von bua321 am 20.01.08 17:39:25

Are apatite nanoparticles safe?

Neva Ciftcioglu a c , Katja M Aho b, David S McKay a and E Olavi Kajander b c

The biosafety of nanomaterials has attracted much attention recently (April 7, p 1142).1,2 Surprisingly, no extensive studies have yet been done on “engineered” nanoparticles in relation to adsorption, biodistribution, metabolism, and excretion.

Calcium phosphate (apatite) deposition in soft tissue is common in inflammatory and autoimmune diseases, and is a threat for organ damage.3 Yet apatite particles have recently been proposed for human use as a vehicle for vaccination, drug delivery, and stent medication. Apatite particles are also used as tissue fillers and advocated as safe and biocompatible.4 However, apatite fillers frequently cause inflammation, macrophage infiltration, and the formation of giant multinucleated cells and fibrous capsules around the particles in soft tissue.4

We report here an incident in which accidental human eye exposure to biogenic nanosized calcium phosphate in the form of calcifying nanoparticles raised a strong IgG immune response against proteins carried by the nanoparticles. The antibody titre has persisted over 10 years at a high level.

The incident occurred to a female scientist at a research laboratory in Finland in 1993. Calcifying nanoparticles, also termed “nanobacteria”, are unique self-replicating agents that deposit calcium phosphate in the size range of 100–300 nm.5 They have not been fully characterised, and no data on biohazards were available at that time. Before the accident, the researcher's serum samples were negative for both calcifying nanoparticle antigen and antibodies against calcifying nanoparticles, as measured by specific ELISA (Nanobac Oy, Kuopio, Finland). While working in the laboratory, high-pressure pipetting caused a calcifying nanoparticle pellet to splash into the researcher's right eye. Both eyes were immediately washed with water and saline.

3 months after the accident, blood and urine samples were tested for calcifying nanoparticle cultures,5 and calcifying-nanoparticle-specific ELISA and blood cell counts were done. Blood cell counts were normal, and calcifying nanoparticles antigen and culture tests were negative. However, a high IgG antibody titre against calcifying nanoparticles was detected (figure). The researcher's antibodies have been used since as a positive control and standard in ELISA manufacturing (Nano-Sero IgG ELISA, Nanobac Oy, Kuopio, Finland).


Click to enlarge imageFigure. Follow-up of laboratory worker's antibodies against calcifying nanoparticles during 12 year-follow-up
Conjuctival pouch exposure to calcifying nanoparticles occurred at 60 months. The ELISA test is done for a serum dilution of 1:500. Measuring range is 0–8 U/mL and values >8 U/mL are presented as 8.

Studies are needed on the mechanisms of these potentially pathogenic particle-mediated immunological reactions. Because of this researcher's documented strong immune response against calcifying nanoparticles, we recommend testing and caution before using fine-grained apatite in applications requiring insertion into the human body.

Nanobac Pharmaceuticals is the manufacturer of the ELISA kits used in this research. NC and EOK own stocks in that company.

References
1. The Lancet.com

Gruss Springbok

[springbok]

Articles by Kajander, E. O.
Articles by Çiftçioglu, N.
Search for Related Content

PubMed

PubMed Citation
Articles by Kajander, E. O.
Articles by Çiftçioglu, N.
Pubmed/NCBI databasesMedline Plus Health Information
Kidney Stones



Medical Sciences
Nanobacteria: An alternative mechanism for pathogenic intra- and extracellular calcification and stone formation

E. Olavi Kajander* and Neva Çiftçioglu
Department of Biochemistry and Biotechnology, University of Kuopio, P.O.B. 1627, Fin-70211, Kuopio, Finland

Calcium phosphate is deposited in many diseases, but formation mechanisms remain speculative. Nanobacteria are the smallest cell-walled bacteria, only recently discovered in human and cow blood and commercial cell culture serum. In this study, we identified with energy-dispersive x-ray microanalysis and chemical analysis that all growth phases of nanobacteria produce biogenic apatite on their cell envelope. Fourier transform IR spectroscopy revealed the mineral as carbonate apatite. The biomineralization in cell culture media resulted in biofilms and mineral aggregates closely resembling those found in tissue calcification and kidney stones. In nanobacteria-infected fibroblasts, electron microscopy revealed intra- and extracellular acicular crystal deposits, stainable with von Kossa staining and resembling calcospherules found in pathological calcification. Previous models for stone formation have led to an hypothesis that elevated pH due to urease and/or alkaline phosphatase activity is a lithogenic factor. Our results indicate that carbonate apatite can be formed without these factors at pH 7.4, at physiological phosphate and calcium concentrations. Nanobacteria can produce apatite in media mimicking tissue fluids and glomerular filtrate and provide a unique model for in vitro studies on calcification.


This article has been cited by other articles in HighWire Press-hosted journals:

Quelle:
Lancet Medical Journal of Britten

Gruss Springbok

[paloma]

Erst mal Patentrechte rechtlich absichern, bevor die kommen.

Nanobac Pharmaceuticals Inc. Engages Legal Team to Enforce Patent Rights

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company”) is pleased to announce that it has engaged Guy Ricciardulli for services related to claims for damages, injury or loss out of patent infringement.

“We are pleased to have Guy and his exceptional team working with us on protecting our intellectual property estate,” stated John Stanton, Nanobac’s Chairman and CEO. “We are at a true turning point at Nanobac with our science, our products and our partnerships, and we need to protect our intellectual property estate.”

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

Source: Business Wire (February 7, 2008 - 9:23 AM EST)

News by QuoteMedia
www.quotemedia.com

[23_2011]

hier ein interessanter link:

http://video.aol.com/video-detail/first-live-video-of-calcif…


mfg

[springbok]

Antwort auf Beitrag Nr.: 33.329.998 von 23_2011 am 11.02.08 14:22:41

Bitte in eine URL verwandeln.

[DepotShadow]

Antwort auf Beitrag Nr.: 33.510.797 von springbok am 29.02.08 00:58:38

http://video.aol.com/video-detail/first-live-video-of-calcif…" target="_blank" rel="nofollow ugc noopener">http://video.aol.com/video-detail/first-live-video-of-calcif…

[springbok]

Antwort auf Beitrag Nr.: 33.526.565 von DepotShadow am 02.03.08 06:38:09

Danke für die URL.

Das ist ein grosser Schritt weiter,in punkto Medizinresearch,wenn nicht sogar der Durchbruch!!!!!
Daher auch der Wunsch das alle Patente geschützt sind und neue angemelded werden.

Gruss Springbok

[paloma]

Nanobac Pharmaceuticals, Inc. Announces Collaboration Agreement With BioChemics for Transdermal Therapeutic Formulation

Nanobac Pharmaceuticals, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company") is pleased to announce the signing of a research collaboration agreement with BioChemics Inc. (BCI) to utilize BCI's leading patented drug delivery technology (VALE®) for the transdermal (topical) delivery of Nanobac compounds for the treatment of prostatitis. Terms of the deal include upfront payments already made, future payments, R&D support as well as milestones for success for BCI.

"The Company believes that utilizing BCI's proprietary transdermal therapeutic delivery system will be beneficial to prostatitis patients due to a more targeted approach of the active ingredient/molecule," said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals. "Through this collaboration with BCI we have now gained access to a promising targeted drug therapy that potentially allows us to address an area of high medical importance where current therapies are clearly inadequate," Dr. Maniscalco concluded.

"Based on the nature of this disease, we believe that the combination of Nanobac's active pharmaceutical agent combined with BCI's drug delivery technology may provide a more efficacious treatment therapy for patients suffering from prostatitis," said John J. Masiz, Esq., President & CEO of BioChemics. "BCI is extremely excited about this collaboration because we see the broader applications in this and other diseases where a targeted transdermal approach may be a better option than oral or i.v. routes of administration," concluded Masiz.

About Prostatitis/CPPS

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) suggest that Prostatitis might account for up to 25 percent of all office visits by young and middle-aged men for complaints involving the genital and urinary systems. The term prostatitis actually encompasses four disorders: Acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain syndrome (CPPS) and Asymptomatic inflammatory prostatitis. CPPS is the most common but least understood form of prostatitis. It is found in men of any age and its symptoms have a profound effect on quality of life. Symptoms include pain (pelvic and genitals), urinary frequency and erectile dysfunction.

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals is the leader in research and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac Pharmaceuticals markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases. Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

About BioChemics, Inc.

BioChemics is a pharmaceutical company that has developed a novel, transdermal drug delivery system for the first time that may allow almost any drug to be efficiently delivered through the skin. The transdermal technology, called VALE® (Vaso-active Lipid Encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents. The company's focus is on multi-billion dollar market opportunities currently underserved by existing therapies. The company's two lead clinical products focus on treating diabetic neuropathy and osteoarthritis. Founded in 1989, the Company is headquartered in Danvers, Mass. Additional information is available at www.biochemics.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

VALE® is a registered trademark of BioChemics, Inc.

Contact:
Nanobac Pharmaceuticals, Tampa
Brady Millican
813-264-2241
Email Contact

BioChemics, Inc.
David H. Donabedian, Ph.D.
COO & SVP, Business Development
[phone]


Source: Marketwire (March 25, 2008 - 9:47 AM EDT)

News by QuoteMedia
www.quotemedia.com